



HAL
open science

Accuracy of PHQ-9 against psychiatric diagnosis for depression among people living with HIV: A multicounty cross-sectional study

Marcel Yotebieng, Natalia Zotova, Charlotte Bernard, Suzanne Goodrich, Ajeh Rogers Awoh, Dana Watnick, Dominique Mahambu Nsonde, Elodie Flore Tchiengang Moungang, Julie Laure Nguemo Noumedem, Guy Calvin Nko'O Mbongo'O, et al.

► To cite this version:

Marcel Yotebieng, Natalia Zotova, Charlotte Bernard, Suzanne Goodrich, Ajeh Rogers Awoh, et al.. Accuracy of PHQ-9 against psychiatric diagnosis for depression among people living with HIV: A multicounty cross-sectional study. AIDS. Official journal of the international AIDS Society, 2024, 10.1097/QAD.0000000000003963 . hal-04654193

HAL Id: hal-04654193

<https://hal.science/hal-04654193>

Submitted on 19 Jul 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

OPEN

AIDS, Publish Ahead of Print

DOI: 10.1097/QAD.0000000000003963

Accuracy of PHQ-9 against psychiatric diagnosis for depression among people living with HIV: A multicounty cross-sectional study

Marcel Yotebieng, PhD,¹ Natalia Zotova, PhD,¹ Charlotte Bernard, PhD,² Suzanne Goodrich, MD,³ Ajeh Rogers Awoh, PhD,⁴ Dana Watnick, PhD,⁵ Dominique Mahambu Nsonde, MD,⁶ Elodie Flore Tchiengang Mougang, MPH,⁴ Julie Laure Nguemo Noumedem, MPH,⁴ Guy Calvin Nko'o Mbongo'o, MD,^{7,8} Albert Minga, MD, PhD,⁹ Moussa Seydi, MD, PhD,¹⁰ Paul Gandou, MD,⁶ Edith Kamaru Kwobah, PhD,¹¹ Lukoye Atwoli, PhD,^{12,13,14} Antoine Jaquet, MD, PhD,² Kara Wools-Kaloustian, MD,³ Kathryn Anastos, MD,¹, on behalf of the IeDEA Consortium

¹ Division of General Internal Medicine, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA

² University of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, Bordeaux, France

³ Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA

⁴ Clinical Research Education and Consultancy, Yaoundé, Cameroon

⁵ Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA

⁶ Centre de Traitement Ambulatoire, Brazzaville, Republic of Congo

⁷ Department of Psychiatry, Jamot Hospital, Yaoundé, Cameroon

⁸ Faculty of Medicine and Pharmaceutical Sciences of Dschang, Dschang, Cameroon

⁹ Centre médical de suivi des donneurs de sang (CNTSCI), Abidjan, Côte d'Ivoire

¹⁰ Service de maladies infectieuses et tropicales, CHNU de Fann, Dakar, Senegal

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

¹¹ Moi Teaching and Referral Hospital, Eldoret, Kenya

¹² Department of Mental Health and Behavioural Sciences, Moi University School of Medicine, Eldoret, Kenya

¹³ Department of Internal Medicine, Medical College East Africa, the Aga Khan University, Nairobi, Kenya

¹⁴ Brain and Mind Institute, the Aga Khan University, Nairobi, Kenya.

Funding

NIAID U01AI096299-08S1, administrative supplement; NIAID U01AI069919, U01AI069911 National Center for Advancing Translational Sciences, UL1TR001070. Einstein-Rockefeller-CUNY Center for AIDS Research (P30-AI124414).

Short title: Accuracy of PHQ-9 among people living with HIV

ABSTRACT

Objective: The aim of this study was to assess the performance of the 9-item Patient Health questionnaire (PHQ-9) against psychiatrist diagnosis in PLWH.

Design: Cross-sectional analysis of data collected between January 2018 and July 2022 across five sites in Cameroon, Cote d'Ivoire, Kenya, Senegal, and the Republic of Congo. Participants were ≥ 18 years and receiving HIV care at the participating site. PHQ-9 was administered by study staff followed by a psychiatrist's evaluation within 3 days.

Results: Overall, 778 participants with complete data were included: 297 (38.2%) in Cameroon, 132 (17.0%) in Congo, 148 (19.0%) in Cote d'Ivoire, 98 (12.6%) in Kenya, and 103 (13.2%) in Senegal. The area under the curve for PHQ-9 score was generally high ranging from 0.935 (95% CI: 0.893, 0.977) in Cote d'Ivoire to 0.768 (95% CI: 0.589, 0.947) in Congo. However, for the common cut-off score ≥ 10 , sensitivity was low: 50% or lower in Cameroon, Congo and Senegal, 66.7% in Kenya and 70.6% in Cote d'Ivoire. But negative predictive values (NPV) were high: 98.9% (95% CI: 96.9%, 99.8%) in Cameroon, 96.1 (95% CI: 91.1, 98.7) in Cote d'Ivoire, 96.3% (95% CI: 89.7%, 99.2%) in Kenya, 95.7% (95% CI: 90.2%, 98.6%) in Congo, and 89.0% (95% CI: 81.2%, 94.4%) in Senegal.

Interpretation: Across all countries, PHQ-9 score ≥ 10 performed very poorly (low sensitivity) as a tool to identify psychiatrist diagnosed depression. However, the observed high NPV suggests it can be used to rule out depression.

Keywords: Depression, PHQ-9, HIV, sensitivity, Specificity, Sub-Saharan Africa

Author summary

Why Was This Study Done? Depression is common among people living with HIV (PLWH) and negatively impacts adherence to the care cascade and clinical outcomes. Yet, despite the availability of effective non-pharmacological and pharmacological interventions to address depression, integration of depression management into HIV care, particularly in the high burden low-resource settings of sub-Saharan Africa, has been limited due to the lack of clinical expertise in identifying depression. To overcome this challenge, structured instruments are often used to generate ratings of patient symptoms. The rating scores are then used to define cases or measure their severity. Among screening instruments for depression, the nine-item Patient Health Questionnaire (PHQ-9) is widely preferred and has been used in clinical trials assessing the integration of depression management on HIV care and clinical outcomes. However, though PHQ-9 was found to have high sensitivity (88%) and specificity (89%) using a score cut off of ≥ 10 for major depression in the United States among people not living with HIV, to the best of our knowledge its performance has not been assessed against a psychiatrist's diagnosis in PLWH in African settings.

What Did the Researchers Do and Find? Using a common protocol across five participating sites in Cameroon, Cote d'Ivoire, Kenya, Senegal, and the Republic of Congo, we assessed the performance of PHQ-9 as a tool for identifying depression in PLWH. Overall, across the three countries, we found that PHQ-9 has low sensitivity and low positive predictive value (PPV) compared to diagnosis made by a psychiatrist, but high negative predictive values (NPV).

What Do These Findings Mean? PHQ-9 as currently formulated performed very poorly (low sensitivity and PPV) as a tool to identify psychiatrist diagnosed depression and caution must be exercised before using it as the only guide to initiating PLWH on pharmacological treatment. However, given the observed high NPV, it can be used to rule out depression or to identify those to be referred for further evaluation.

INTRODUCTION

Depression is common among people living with HIV (PLWH) and affects their quality of life, adherence to antiretroviral therapy, and viral suppression [1-4]. A timely diagnosis of major depressive disorder (MDD) and treatment is thus essential for retention in care, better quality of life, and clinical outcomes among PLWH [5-8]. Affordable pharmacological and non-pharmacological interventions exist but access is limited because of challenges identifying depression, particularly in people with pre-existing conditions like HIV [9-11]. Diagnosis requires the exercise of clinical judgment, assessment of symptom severity and functional impairment, and the exclusion of alternative medical or psychiatric explanations for symptoms [12].

In low-resource settings where such expertise is scarce, structured instruments are often used by non-specialists as an alternative diagnostic technique to generate ratings of patient symptoms. The rating scores are then used to define cases of a depressive syndrome or measure its severity [13].

Among the screening instruments, the nine-item Patient Health Questionnaire (PHQ-9) is widely preferred [14]. The PHQ-9 was originally developed to screen for and identify severity of depression in American adults in clinical settings via patient self-administration. This instrument is based on the diagnostic criteria for DSM-IV MDD and its total score ranges from 0 to 27. When treated as unidimensional and sum-scored, the PHQ-9, using a score threshold of ≥ 10 , has been found to have high sensitivity (88%) and specificity (89%) for MDD compared to a psychiatrist's diagnosis used as a reference, in United States [14]. Assessments of the PHQ-9 performance in non-Western contexts remain limited. The tool has been minimally evaluated for comprehension and overall performance, particularly in low-resource settings with high HIV burden [15-16]. Studies from sub-Saharan Africa that examined the PHQ-9's validity among different population groups include those in Cameroon, Ethiopia, Ghana, Kenya, Malawi, Nigeria, South Africa, and Uganda [12]. Only three of these studies assessed the PHQ-9's performance among PLWH. These studies provided mixed evidence on the PHQ-9's performance in identifying depression with a sensitivity and specificity of 27% and 94% in Cameroon (Gold Standard: Composite International Diagnostic Interview), and 78.7% and 83.4% in South Africa (Gold Standard: Mini International Neuropsychiatric Instrument [MINI]) [17-18]; and 91.6% and 81.2% in Uganda (Gold Standard: MINI) [19].

Reasons for the large variability in PHQ-9's performance among PLWH in sub-Saharan Africa have not been investigated. The role of culture has emerged as a salient concern because as a general trend, members of many cultures express mental distress by way of somatic complaints rather than the more psychological affective and cognitive manifestations that are considered the hallmarks of depression in a Western context [20-22]. A similar concern emerges when assessing depression in populations with co-morbid conditions like HIV, because the symptoms assessed may occur as a result of depression, HIV, side effects of antiretroviral therapy (ART), or opportunistic infections. Given these findings, if the PHQ-9 (or the shorter PHQ-2) is to be used to diagnose and initiate PLWH on pharmacological or non-pharmacological interventions, as it has been done in reported trials of integration of depression management in HIV care [23, 24], assessment of its performance against a psychiatrist's diagnosis in this population is urgently needed.

This study was designed to assess the performance of PHQ-9 as a tool to identify MDD against a diagnosis by a psychiatrist.

METHODS

Design, setting, and population

This cross-sectional study was conducted across five countries participating in the International Epidemiology Databases to Evaluate AIDS (IeDEA): two within the Central Africa IeDEA (Brazzaville Ambulatory Treatment Center, the Republic of Congo and Yaoundé Jamot Hospital, Cameroon), two within the West Africa IeDEA (Medical center for blood donor follow-up (CNTS-CI) in Abidjan Cote d'Ivoire and Department of Infectious and Tropical Diseases, CHNU Fann Dakar, Senegal), and one in East Africa IeDEA (AMPATH clinic at Moi Teaching and Referral Hospital in Eldoret, Kenya). Participating hospitals are in urban areas, serve large active cohorts of PLWH, and were selected because of onsite psychiatric services. Within each site in Cameroon,

Congo, and Kenya, a sample of PLWH, 18 years and older, enrolled in care at the site at least 3 months prior (to avoid the high anxiety associated with initial diagnosis that, while it may become depression for some, is more anxiety and fear-driven and may confound measurement of depression [25]) and for less than 24 months HIV care enrollment were eligible for the study. The sample inclusion criteria were applied in Cote d'Ivoire and Senegal, except for the requirement to be enrolled in HIV care for less than 24 months. Participants were excluded if they were not fluent in any of the languages in which the questionnaire was translated (English, French, Lingala, Kituba, Luo, and Swahili), unable to consent, or declined to participate in the study. At each participating site, health care providers shared brief information about the study to potential participants during routine care visit at the participating clinic. Individuals who expressed their interest were then referred to the study staff who assessed their eligibility and conducted informed consent. Study staff then administered the PHQ-9 questionnaire and following administration took the participant to the psychiatrist for evaluation within 3 days. All enrolled participants provided written consent and were compensated for their time and transport to the clinic (\$3 in local currency). Any mental disorder diagnosed during psychiatrist evaluation was managed according to standard local protocol including in interpersonal group therapy or pharmacologic management for depression. The study was approved by the Ohio State University Institutional Review Board (Protocol #2018H0195), Albert Einstein College of Medicine Institutional Review Board (#2018-9355), Regional Ethics Committee for Research on Human Health in Cameroon (#1846/CRERSHC/2019), Moi University College of Health Sciences and Moi Teaching and Referral Hospital's Institutional Research and Ethics Committee, Kenya (#3329/IREC/2019/57), the Indiana University Institutional Review Board (#1810880690), the Comite d'Ethique de la Recherche en Sciences de la Sante in Congo (#017/CEI/FCRM/2018), the National Ethics Committee for Health Research in Senegal (#00036/MAS/CNERS/SP), and the National Ethics Committee for Health and Life Sciences in Cote d'Ivoire (#013-21/MSHP/CNESVS-km).

Assessments

The English, French, and Swahili versions of the PHQ-9 were retrieved from the Pfizer Patient Health Questionnaires website [26]. In Congo, the country team translated the PHQ-9 from French to Lingala and Kituba and then, back-translated to French, and field tested the translated versions as in previous study [8].

Trained research assistants administered the PHQ-9 and a questionnaire that collected socio-demographic information. A PHQ-9 score ≥ 10 , indicating moderate to severe depression, was used to identify probable depressed individuals [27]. After completing the questionnaire, participants were referred to a psychiatrist with experience working with PLWH, who independently evaluated them for MDD within 3 days (except in Kenya all assessments were completed on the same day). Psychiatrists were blinded to the PHQ-9 scores. At all sites, because MINI is not routinely used, for standardization purposes, psychiatrists were provided with MINI and encouraged to use it to guide their evaluation. But no data on MINI was collected as we did not receive permission to use it for this research. In addition, in both Central and East Africa, psychiatrists were provided with a separate diagnosis form to complete at the end of the participant visit and returned to the study team. The diagnosis form asked psychiatrists to evaluate each participant for a diagnosis of Major Depressive

Episode/Disorder and Generalized Anxiety Disorder among other. Psychiatrists indicated “Yes” or “No” for each diagnosis. If a participant met similar criteria for a diagnosis but did not meet the DSM-5 criteria in full, they could indicate “Not Specified”. If a positive diagnosis was selected, the psychiatrist specified the time frame in which the symptoms occurred: e.g. corresponding time period: current (over the “past two weeks”), recent (within the past year), or past (over one year ago).

Analyses

Proportions, means, and medians were used to summarize participants’ socio-demographic characteristics. The extent to which the PHQ-9 is able to identify the likely presence or absence of depression was assessed using sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV), positive and negative likelihood ratio (LR), and areas under the curve (AUC). The psychiatrist’s diagnosis was used as a gold standard. Sensitivity and specificity with corresponding exact binomial 95% confidence intervals (CI) were calculated as the proportion of participants with depression and the proportion without depression respectively, who were correctly classified as such based on their PHQ-9 score ≥ 10 , respectively. The following alternative PHQ-9 score cut-offs of >4 , >7 , >11 , >14 , >17 , and >19 were also considered [29]. We also performed the same analyses for the PHQ-2 (i.e., the first two items of the PHQ-9) using a cut-off score of ≥ 3 for defining depression. Psychometric assessments including Cronbach alpha (for internal consistency of the PHQ-9) and exploratory factor analyses was also performed to assess the PHQ-9’s dimensional structure among PLWH. Analyses were stratified by the country/clinic and language of interview. All statistical analyses were completed using SAS 9.4 (SAS Institute, Cary, NC).

RESULTS

Participants’ characteristics

Overall 1,064 PLWH were screened for participation; 422 in Cameroon (January 2018-December 2019); 348 in Congo (January 2019-April 2019), 294 in Kenya (February 2020-June 2021), 148 in Cote d’Ivoire (March 2021 – May 2021), and 103 in Senegal (March 2021 – July 2022). Of those, 779 had a completed psychiatric evaluation form and were included in the analyses including 297 (38.2%) in Cameroon, 132 (17.0%) in Congo, 148 (19.0%) in Cote d’Ivoire, 98 (12.6%) in Kenya, and 103 (13.2%) in Senegal. The main reason for missing the psychiatric diagnosis was the unavailability of the psychiatrist as only one potential participant screened, declined to take part in the study. The median age was 41 years (range 19-69) in Cameroon, 41 (range 22-74) in Congo, 48 (range 40-56) in Cote d’Ivoire, 36 (range 21-69) in Kenya, and 46 (range 35-55) in Senegal (Table 1). About one-third in Kenya and Congo, and one-half of participants in Cameroon, Cote d’Ivoire and Senegal were male. Respectively, 31.7% (n=95) in Cameroon, 19.7% (n=26) in Congo, 41.2% (n=61) in Cote d’Ivoire, 38.8% (n=38) in Kenya, and 61.0% (n=62) in Senegal had completed no more than primary education. PHQ-9 was administered to most participants (78.1%, n=612) in French, including 97.0% (n=291) of participants in Cameroon, 53.0% (n=70) in Congo and all participants from Cote D’Ivoire and Senegal. Sixty participants (61.2%) in Kenya and 55 (41.7%) in Congo were interviewed in Swahili and Lingala, respectively.

PHQ-9 and PHQ-2 scores and Psychiatric diagnoses

The median PHQ-9 scores were 2 (range 0-21) in Cameroon, 4 (range 0-19) in both the Congo and Kenya, 3 (range 0-22) in Cote d'Ivoire and 2 (range 0-14) in Senegal. The median PHQ-2 scores were 0 in Cameroon (range 0-6) and Senegal (range 0-6), 1 (range 0-6) in Congo and Cote d'Ivoire, and 1.5 (range 0-6) in Kenya, respectively. Overall, 6.0% (n=18) participants in Cameroon, 11.5% (n=17) in Cote d'Ivoire, 13.6% (n=14) in Senegal, 17.4% (n=23) in Congo, and 34.0% (n=33) in Kenya were found by a psychiatrist to have MDD (Table 2).

Characteristics of PHQ-9 and PHQ-2 against Psychiatric diagnosis

Table 3 presents data on sensitivity, specificity, PPV and NPV of the PHQ-9 (scores > 4, 7, 9, 11, 14, 17, and 19), PHQ-2 (score ≥ 3) and the CDQ major and other depression syndrome against psychiatrist's diagnosis. Overall, across countries, the sensitivity of the PHQ-9 for current MDD was low, ranging from 8.0% (95% CI: 0.2, 38) in Senegal, 50.0% (95% CI: 11.8%, 88.2%) in Cameroon 50.0% (95% CI: 18.7%, 81.3%) in Congo, 66.7% (95% CI: 29.9%, 92.5%) in Kenya, to 70.6% (95% CI: 44.0%, 99.0%) in Cote d'Ivoire for PHQ-9 score ≥ 10 . This sensitivity was similar to that of PHQ-2 score ≥ 3 : 25.0% (95% CI: 5.5%, 57.2%) in Senegal, 30.0% (95% CI: 6.7%, 65.3%) in Congo, 50.0% (95% CI: 11.8%, 88.2%) in Cameroon, 55.6% (95% CI: 21.2%, 86.3%) in Kenya, and 64.7% (95% CI: 38.3%, 85.8%) in Cote d'Ivoire. When stratified by the language of interview (Supplemental Table S1, <http://links.lww.com/QAD/D261>), despite the wider confidence intervals, there was more variations with sensitivity as low as 44.7% (95% CI: 28.6%, 61.7%) for interviews in French, 62.5% (95% CI: 24.5%, 91.5%) for Swahili, and 75.0% (95% CI: 19.4, 99.4) for Lingala.

The PPVs was also relatively low ranging from 17.7% (3.8%, 43.3%) in Cameroon, to 29.4% (95% CI: 10.3%, 56.0%) in Congo, 37.5% (95% CI: 15.2%, 64.6%) in Kenya, and 60.0% (95% CI: 36.1%, 80.9%) in Cote d'Ivoire, for a score ≥ 10 . On the other hand, the NPVs were generally quite high (Table 4). The probability of not having a current MDD when one was screened negative based on the PHQ-9 score ≥ 10 was 98.9% (95% CI: 96.9%, 99.8%) in Cameroon, 95.7% (95% CI: 90.2%, 98.6%) in Congo, 96.3% (95% CI: 89.7%, 99.2%) in Kenya, and 96.1% (95% CI: 91.1%, 98.7%) in Cote d'Ivoire. PHQ-2 with cut-off at ≥ 3 also had similar high NPV (Table 4). Using the CDQ definition of MDD or other depression produces lower or similar performance against the goal standard.

The positive likelihood ratios (LR+) range from 5.08 (95% CI: 0.91, 9.25) in Congo and 5.93 (95% CI: 1.52, 10.35) in Kenya to 10.40 (95% CI: 0.53, 20.26) in Cameroon and 11.56 (95% CI: 3.03, 20.09) in Cote d'Ivoire for a PHQ-9 score ≥ 10 . The LR+ for PHQ-2 range from 1.22 (95% CI: 0.00, 2.44) in Congo and 2.15 (95% CI: 0.68, 3.62) in Kenya, 3.39 (95% CI: 1.70, 5.08) in Cote d'Ivoire, to 4.28 (95% CI: 0.60, 7.96) in Cameroon and 7.42 (95% CI: 0.00, 18.41) for a score ≥ 3 (Table 5).

When the analysis was stratified by the language of interview (Table S1, <http://links.lww.com/QAD/D261>), the sensitivity of the PHQ-9 score ≥ 10 for the diagnosis of any

MDD was lowest for French 44.7% (95% CI: 28.6%, 61.7%), followed by and Swahili 62.5% (95% CI: 24.5%, 91.5%), and Lingala 75.0% (95% CI: 19.4%, 99.4%).

The AUC did not vary substantially by country or language (Supplemental Table S2, <http://links.lww.com/QAD/D261>). The AUC for the continuous PHQ-9 score varied from 0.935 (95% CI: 0.893, 0.977) in Cote d'Ivoire, 0.888 (95% CI: 0.784, 0.992) in Cameroon, 0.866 (95% CI: 0.775, 0.958) in Senegal, 0.802 (95% CI: 0.603, 1.00) in Kenya, to 0.768 (95% CI: 0.589, 0.947) in Congo or from 0.875 (95% CI: 0.829, 0.921) for French, 0.855 (95% CI: 0.570, 1.000) for Lingala, to 0.759 (95% CI: 0.541, 0.978) for Swahili.

Psychometric analyses of PHQ-9 for HIV patients

Overall, the internal consistency of PHQ-9 items was acceptable with Cronbach's alpha varying from 0.80 in Cameroon and Kenya, 0.78 in Senegal, 0.72 in Cote d'Ivoire, to 0.69 in Congo. Except for Lingala in Congo, the language of the interview did not appear to influence the internal consistency of the PHQ-9 with Cronbach's alpha varying from 0.81 for English, to 0.76 for French, 0.79 for Swahili, and 0.66 for Lingala (Supplemental Table S2, <http://links.lww.com/QAD/D261>).

In exploratory principal component factor analysis, in the overall combined sample or in stratified sample by country, only one factor had Eigenvalue ≥ 1 . However, in the analysis stratified by language, two factors meet the same criteria for interviews conducted in Swahili. Eigenvalue for factor 2 in the English sample was 0.82, 0.63 in the Lingala group, and only 0.34 among those interviewed in French (Supplemental Table S3, <http://links.lww.com/QAD/D261>).

Among those interviewed in French, all items have a Factor 1 loading between 0.46 and 0.56. Across all four languages, Items 2 and 6 loaded consistently high and item 5 consistently low on Factor 1. The loading of the remaining six items depended on the language of the interview. For those interviewed in Lingala, Item 1 ("Interest"), Items 3 ("Sleep"), 4 ("Tired"), and 7 ("Concentration") had factor loading < 0.40 while items 9, 6, and 2, respectively, had the first (0.69), second (0.64), and third (0.63) highest loading on Factor 1 (Table 4). Among those interviewed in Swahili item 8 ("Slowdown") was the only item with factor 1 loading < 0.40 . Item 7 ("Concentration"), 2 ("depressed"), and 4 ("Tired") have factor 1 loading of 0.83, 0.73, and 0.61, respectively. For those interviewed in English only two items have factor loading < 0.50 : Items 7 ("Concentration"); 0.25 and 5; 0.39 (Supplemental Table S3, <http://links.lww.com/QAD/D261>).

Discussion

The PHQ-9 has been proposed as a screening tool for MDD and is being used as such to support integration of depression management into HIV care in sub-Saharan Africa [23, 24]. In this multi-country study, we found the sensitivity and PPV of PHQ-9 were generally low when compared to a diagnosis assigned by a psychiatrist, irrespective of the cut-off considered. We also found that, regardless of the country or the language of evaluation, the NPV was very high, confirming the usefulness of PHQ-9 as a good tool to screen for the absence of depression symptoms, particularly in setting of relatively low prevalence.

Our findings of low sensitivity and PPV of the PHQ-9 across cultural contexts of Central, East-Africa, and West Africa are consistent with the existing literature on the use of PHQ-9 from the region and beyond [28]. The low PPV even in context of high depression, is a call for caution for those tempted to use the PHQ-9 as a diagnostic tool and more critically, to suggest that patients who screen positive be initiated on pharmacological treatment without additional evaluations to confirm diagnosis of MDD [29].

The performance of the PHQ-9 varied across the five countries in our study with lower sensitivity observed in Cameroon and the highest in Cote d'Ivoire. This is consistent with what has been reported in previous studies as discussed in the introduction. However, the magnitude of the variation is substantially smaller in our single protocol study, suggesting that at least part the previously observed variations may stem from protocol differences, rather than from underlining cultural differences. Originally, we had planned in this study to use MINI to standardize depression diagnosis across setting, unfortunately MINI is proprietary and the author and copyright order did not give us the permission. We also noticed differences based on the language used in the administration of the interviews, but the limited sample size for English interviews, did not allow us to explore this difference deeper. However, such variation coupled with the differential loading of item by language interview, suggest a difficulty in understanding of at least some question in some language. But whether this is due to a translation or cognition problem needs to be explored.

There is growing evidence supporting that the PHQ-9 as a two-factor instrument [30, 31]. Yet in our exploratory factor analysis, the second eigenvalue was > 0.5 only in Kenya. When analysis was performed by language, the eigenvalue of the second factor was >1 for Swahili (used only in Kenya together with English), and >0.5 for Lingala (used only in Congo). This suggests that at least, there are some difficulties as related to comprehension of questions depending on how fluent in the language of interview one is and may explain the low performance of PHQ-9.

The strengths of this study include the use of a common protocol across all five participating sites and the availability of a diagnosis by a psychiatrist. However, the study also had important limitations: 1) the PHQ-9 was administered by interviewers due to some participants' low literacy; the questionnaire was originally designed to be self-administered. 2) the inability to enroll 300 participants as planned at all sites due to COVID-19 pandemic. A larger sample in Congo and in Kenya would have allowed us to deepen the analysis by languages, particularly the comparison of Kituba and Lingala in Congo or Swahili and English in Kenya. In addition, because of the smaller than planned sample size, our estimates have wide confidence intervals, weakening the strength of our conclusion. 3) The study was conducted in urban settings with over two-thirds of participants having completed at least elementary school. Performance of the PHQ-9 in a rural, less educated sample of participants is likely to differ. 5) In addition to COVID interruption, the limited availability of psychiatrist at each site means some patients who consent to be part of the study were not evaluated (except in Cote d'Ivoire and Senegal), further limiting the available sample size. 6) we had planned to perform in-depth interviews in each country to better assess the source of differences in PHQ-9 across countries, however, we were able to complete this only in Cameroon due to COVID interruption.

In conclusion, PHQ-9 performed very poorly (low sensitivity and PPV) as a screening tool for depression. However, the observed high NPV suggests that PHQ-9 can be used to identify PLWH who should be referred for further evaluation because we cannot rule out depression.

Declaration of interests

All authors declare no conflict of interest.

Acknowledgements

This study was funded via an administrative supplement to the Central Africa International epidemiology Database to Evaluate AIDS (IeDEA) grant from National Institute of health (NIAID U01AI096299-08S1). The Redcap Database was supported by a grant from the National Center for Advancing Translational Sciences (UL1TR001070). Moi Teaching and Referral Hospital is a participating site of the East Africa IeDEA also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U01AI069911. Medical center for blood donor follow-up (CNTS-CI) in Cote d'Ivoire, and the Department of Infectious and Tropical Diseases (CHNU Fann) in Senegal are participating sites of the West Africa IeDEA which are also supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number U01AI069919

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

We are extremely grateful to study participants for their time and willingness to participate in research. We are also grateful to the staff of the Jamot Hospital in Yaoundé, Centre Ambulatoire de Traitement of Bazzaville, Moi Teaching and Referral Hospital in Eldoret, Medical center for blood donor follow-up (CNTS-CI) in Abidjan and Department of Infectious and Tropical Diseases, CHNU Fann in Dakar and the leadership of IeDEA in each participating country for facilitating the study. Many thanks to Dr. Paul De Boeck, at the Ohio State University and to Dr. Pim Brouwers at NIMH for their feedbacks on the design and analysis of this study.

References

1. Ezeamama AE, Woolfork MN, Guwatudde D, et al. Depressive and Anxiety Symptoms Predict Sustained Quality of Life Deficits in HIV-Positive Ugandan Adults Despite Antiretroviral Therapy: A Prospective Cohort Study. *Medicine* 2016; 95(9): e2525.
2. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. *Journal of acquired immune deficiency syndromes (1999)* 2011; 58(2): 181-7.
3. Ironson G, O'Cleirigh C, Fletcher MA, et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. *Psychosomatic medicine* 2005; 67(6): 1013-21.

4. Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. *AIDS patient care and STDs* 2006; 20(6): 418-28.
5. Stringer, E.M., Meltzer-Brody, S., Kasaro, M., Stuebe, A.M., Wiegand, S., Paul, R., & Stringer, J.S. (2014). Depression, pregnancy, and HIV: The case to strengthen mental health services for pregnant and post-partum women in Sub-Saharan Africa. *The Lancet Psychiatry*, 1(2), 159-162.
6. Bengtson AM, Pence BW, O'Donnell J, et al. Improvements in depression and changes in quality of life among HIV-infected adults. *AIDS care* 2015; 27(1): 47-53.
7. Horberg MA, Silverberg MJ, Hurley LB, et al. Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. *Journal of acquired immune deficiency syndromes (1999)* 2008; 47(3): 384-90.
8. Yotebieng, K. A., Fokong, K., & Yotebieng, M. (2017). Depression, retention in care, and uptake of PMTCT service in Kinshasa, the Democratic Republic of Congo: a prospective cohort. *AIDS care*, 29(3), 285–289. <https://doi.org/10.1080/09540121.2016.1255708>
9. Asch SM, Kilbourne AM, Gifford AL, et al. Underdiagnosis of depression in HIV: who are we missing? *Journal of general internal medicine* 2003; 18(6): 450-60.
10. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 2018 Apr 7;391(10128):1357-1366. doi: 10.1016/S0140-6736(17)32802-7.
11. Farah WH, Alsawas M, Mainou M, Alahdab F, Farah MH, Ahmed AT, Mohamed EA, Almasri J, Gionfriddo MR, Castaneda-Guarderas A, Mohammed K, Wang Z, Asi N, Sawchuk CN, Williams MD, Prokop LJ, Murad MH, LeBlanc A. Non-pharmacological treatment of depression: a systematic review and evidence map. *Evid Based Med*. 2016 Dec;21(6):214-221. doi: 10.1136/ebmmed-2016-110522.
12. Tsai AC. Reliability and validity of depression assessment among persons with HIV in sub-Saharan Africa: systematic review and meta-analysis. *Journal of acquired immune deficiency syndromes (1999)* 2014; 66(5): 503-11.
13. Gibbons RD, Clark DC, Kupfer DJ. Exactly what does the Hamilton Depression Rating Scale measure? *Journal of psychiatric research* 1993; 27(3): 259-73.
14. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *Journal of general internal medicine* 2001; 16(9): 606-13.
15. Malpass 2016 Malpass A, Dowrick C, Gilbody S, Robinson J, Wiles N, Duffy L, Lewis G. Usefulness of PHQ-9 in primary care to determine meaningful symptoms of low mood: a qualitative study. *Br J Gen Pract*. 2016 Feb;66(643):e78-84. doi: 10.3399/bjgp16X683473. PMID: 26823268; PMCID: PMC4723218.

16. Velloza J, Njoroge J, Ngure K, Thuo N, Kiptinness C, Momanyi R, Ayub S, Gakuo S, Mugo N, Simoni J, Heffron R. Cognitive testing of the PHQ-9 for depression screening among pregnant and postpartum women in Kenya. *BMC Psychiatry*. 2020 Jan 29;20(1):31. doi: 10.1186/s12888-020-2435-6. PMID: 31996166; PMCID: PMC6990517.
17. Cholera, R., Gaynes, B. N., Pence, B. W., Bassett, J., Qangule, N., Macphail, C., Bernhardt, S., Pettifor, A., & Miller, W. C. (2014). Validity of the Patient Health Questionnaire-9 to screen for depression in a high-HIV burden primary healthcare clinic in Johannesburg, South Africa. *Journal of affective disorders*, 167, 160–166. <https://doi.org/10.1016/j.jad.2014.06.003>
18. Pence BW, et al. Validity of an interviewer-administered patient health Questionnaire-9 to screen for depression in HIV-infected patients in Cameroon. *J Affect Disord*. 2012; 143(1–3):208–13.
19. Akena D, Joska J, Obuku EA, Stein DJ. Sensitivity and specificity of clinician administered screening instruments in detecting depression among HIV-positive individuals in Uganda. *AIDS Care*. 2013;25(10):1245-52. doi: 10.1080/09540121.2013.764385.
20. Kriegler S, Bester SE. A critical engagement with the DSM-5 and psychiatric diagnosis. *Journal of Psychology in Africa* 2014; 24(4): 393-401.
21. Sweetland AC, Belkin GS, Verdeli H. Measuring depression and anxiety in Sub-Saharan Africa. *Depression and anxiety* 2014; 31(3): 223-32.
22. Ryder AG, Yang J, Zhu X, et al. The cultural shaping of depression: somatic symptoms in China, psychological symptoms in North America? *Journal of abnormal psychology* 2008; 117(2): 300-13.
23. Stockton MA, Minnick CE, Kulisewa K, et al. A Mixed-methods process evaluation: integrating depression treatment into HIV care in Malawi. *Glob Health Sci Pract*. 2021;9(3):611-625. doi:10.9745/GHSP-D-20-00607
24. Wagner GJ, Ngo V, Goutam P, Glick P, Musisi S, Akena D. A Structured protocol model of depression care versus clinical acumen: a cluster randomized trial of the effects on depression screening, diagnostic evaluation, and treatment uptake in Ugandan HIV clinics. *PLoS One*. 2016;11(5):e0153132.
25. Clucas C, Sibley E, Harding R, Liu L, Catalan J, Sherr L. A systematic review of interventions for anxiety in people with HIV. *Psychol Health Med*. 2011;16(5):528-547. doi:10.1080/13548506.2011.579989
26. <https://www.phqscreeners.com/select-screener>. Accessed on 3 September 2022.
27. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. *Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire*. *JAMA*. 1999 Nov 10; 282(18):1737-44.
28. Sweetland AC, Belkin GS, Verdeli H. Measuring depression and anxiety in sub-saharan Africa. *Depression and anxiety* 2014; 31(3): 223-32.
29. Kriegler S, Bester SE. A critical engagement with the DSM-5 and psychiatric diagnosis. *Journal of Psychology in Africa* 2014; 24(4): 393-401.

30. Shafer AB. Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung. *Journal of Clinical Psychology* 2006; 62(1): 123-46.

31. Chilcot J, Rayner L, Lee W, et al. The factor structure of the PHQ-9 in palliative care. *Journal of psychosomatic research* 2013; 75(1):b60-4.

Table 1. Socio-demographic and clinical characteristics of 784 PLWH who completed a PHQ-9 questionnaire and a psychiatrist assessment in Cameroon, Republic of Congo, Cote d'Ivoire, Kenya, and Senegal.

	Cameroon		Congo		Kenya		Cote d'Ivoire		Senegal		Total	
	N	%	N	%	N	%	N	%	N	%	N	%
Age: Median (Range)	297	41 (19, 69)	132	41 (22, 74)	98	36 (21, 69)	148	48 (21, 84)	103	46 (23, 80)	778	42 (19, 84)
Gender												
Male	151	50.8	45	3.1	33	33.7	74	50.0	48	46.6	351	44.9
Female	149	49.2	83	62.9	64	65.3	74	50.0	55	53.4	425	54.4
Missing		0.0	4	3.0	1	1.0					5	0.6
Educational level												
primary	95	31.7	26	19.7	38	38.8	61	41.2	64	62.1	284	36.4
secondary	145	48.2	67	50.8	38	38.8	54	36.5	30	29.1	334	42.8
tertiary	32	10.8	32	24.2	17	17.3	33	22.3	9	8.7	123	15.7
Missing	28	9.4	7	5.3	5	5.1					40	5.1
Interview language												
English	9	3.0	0	0.0	38	38.8					47	6.0
French	291	97.0	70	53.0	0	0.0	148	100.0	103	100.0	612	78.1
Kituba	0	0.0	6	4.5	0	0.0					6	0.8
Lingala	0	0.0	55	41.7	0	0.0					55	7.0
Swahili	0	0.0	0	0.0	60	61.2					60	7.7

Table 2. PHQ-9 scores and psychiatric diagnosis.

	Cameroon		Republic of Congo		Kenya		Cote d'Ivoire		Senegal		Total	
	N	%	N	%	N	%	N	%	N	%	N	%
PHQ-9 score												
Median score (Range)	2 (0-21)		4 (0-19)		4 (0-19)		3 (0-22)		2 (0-14)		3 (0-22)	
0-4	235	78.3	70	53	54	55.1	87	58.8	82	79.6	528	67.8
5-10	48	16	45	34.1	28	28.6	41	27.7	20	19.4	182	23.1
10-14	10	3.3	12	9.1	13	13.3	13	8.8	1	1.0	49	6.3
15-19	6	2	5	3.8	3	3.1	5	3.4	0	0.0	19	2.4
20-27	1	0.3	0	0	0	0	2	1.4	0	0.0	3	0.4
PHQ-2 score												
Median score (Range)	0 (0-6)		1 (0-6)		1.5 (0-6)		1 (0-6)		0 (0-5)		1 (0-6)	
0-2	263	87.7	99	75	70	71.4	104	70.3	93	90.3	629	80.5
3-6	37	12.3	33	25	28	28.6	44	29.7	10	9.7	152	19.5
Psychiatric diagnosis												
Major Depressive Disorder												
Yes	18	6.1	23	17.4	33	33.7	17	11.5	12	11.9	103	13.2
No	278	93.9	109	82.6	65	66.3	131	88.5	89	88.1	672	86.3
Not Specified	3	1	0	0	0	0					3	
Missing	1										1	
Time frame												
Current (over past 2 weeks)	6	35.3	10	45.5	9	27.3	17	100	14	100	56	52.8
Recent (within past year)	7	41.2	0	0	0	0	0	0	0	0	7	6.6
Past (over one year ago)	4	23.5	12	54.5	24	72.7					40	37.7
Missing	1		1		1						3	2.8

Table 3. Sensitivity and specificity of the PHQ-9, PHQ-2 and the CDQ major and other depression syndrome against a psychiatric diagnosis (current depression).

	Overall	Cameroon	Congo	Kenya	Cote d'Ivoire	Senegal
	Sensitivity					
PHQ-9 ≥ 5	83.3 (71.7, 92.4)	83.3 (35.9, 99.6)	80.0 (44.4, 97.5)	88.89 (51.8, 99.7)	100 (80.5, 100)	64.3 (35.1, 87.2)
PHQ-9 ≥ 8	62.5 (48.6, 75.1)	50.0 (11.8, 88.2)	70.0 (34.8, 93.3)	66.7 (29.9, 92.5)	88.2 (63.3, 98.5)	28.6 (8.4, 58.1)
PHQ-9 ≥ 10	48.2 (34.7, 62.0)	50.0 (11.8, 88.2)	50.0 (18.7, 81.3)	66.7 (29.9, 92.5)	70.6 (44.0, 99.0)	7.1 (0.2, 33.9)
PHQ-9 ≥ 12	33.9 (21.8, 47.8)	33.3 (4.3, 77.7)	50.0 (18.7, 81.3)	55.6 (21.2, 86.3)	35.3 (14.2, 61.7)	7.1 (0.2, 33.9)
PHQ-9 ≥ 15	17.9 (8.9, 30.4)	33.3 (4.3, 77.7)	30.0 (6.7, 65.3)	22.2 (2.8, 60.0)	17.6 (3.8, 43.4)	-
PHQ-9 ≥ 18	10.7 (4.0, 21.9)	33.3 (4.3, 77.7)	10.0 (0.3, 44.5)	11.1 (0.3, 48.3)	11.8 (1.5, 36.4)	-
PHQ-9 ≥ 20	8.9 (3.0, 19.6)	33.3 (4.3, 77.7)	0	11.1 (0.3, 48.3)	11.8 (1.5, 36.4)	-
PHQ-2 ≥ 3	46.3 (32.6, 60.4)	50.0 (11.8, 88.2)	30.0 (6.7, 65.3)	55.6 (21.2, 86.3)	64.7 (38.3, 85.8)	25.0 (5.5, 57.2)
CDQ Major depression syndrome*	16.1 (7.2, 28.3)	16.7 (0.4, 64.1)	30.0 (6.7, 65.3)	22.2 (2.8, 60.0)	11.8 (1.5, 36.4)	8.3 (0.2, 38.5)
CDQ Other depression syndrome*	46.4 (33.0, 60.3)	50.0 (11.8, 88.2)	50.0 (18.7, 81.3)	66.7 (29.9, 92.5)	64.7 (38.3, 85.8)	8.3 (0.2, 38.5)
	Specificity					
PHQ-9 ≥ 5	71.6 (68.2, 74.9)	79.7 (74.6, 84.2)	55.7 (46.5, 64.7)	59.6 (48.6, 69.8)	66.4 (57.6, 74.4)	86.5 (77.6, 92.8)
PHQ-9 ≥ 8	86.3 (83.6, 88.7)	91.8 (88.0, 94.6)	74.6 (65.9, 82.0)	75.3 (65.0, 83.8)	84.7 (77.4, 90.4)	97.8 (92.1, 99.7)
PHQ-9 ≥ 10	93.9 (91.9, 95.5)	95.2 (92.1, 97.4)	90.2 (83.5, 94.8)	88.8 (80.3, 94.5)	93.9 (88.3, 97.3)	100 (95.9, 100)
PHQ-9 ≥ 12	96.5 (94.9, 97.8)	96.6 (93.8, 98.7)	94.3 (88.5, 97.7)	95.5 (88.9, 98.8)	97.0 (92.3, 99.2)	100 (95.9, 100)
PHQ-9 ≥ 15	98.3 (97.1, 99.1)	98.3 (96.0, 99.4)	98.4 (94.2, 99.8)	98.9 (93.9, 100)	97.0 (92.3, 99.2)	100 (95.9, 100)
PHQ-9	99.6 (98.8, 100)	99.3 (97.5, 100)	99.2 (95.5, 100)	100 (95.9, 100)	100 (97.2, 100)	100 (95.9, 100)

≥18	99.9)	99.9)	100)			
PHQ-9 ≥20	99.7 (99.0, 100)	99.7 (98.1, 100)	99.2 (95.5, 100)	100 (95.9, 100)	100 (97.2, 100)	100 (95.9, 100)
PHQ-2 ≥3	84.1 (81.2, 86.7)	88.3 (84.1, 91.8)	75.4 (66.8, 82.8)	74.2 (63.8, 82.9)	80.9 (73.1, 87.3)	96.6 (90.4, 99.3)
CDQ Major depression syndrome*	98.3 (97.1, 99.1)	97.6 (95.1, 99.0)	98.4 (94.2, 99.8)	100 (95.9, 100)	97.7 (93.5, 99.5)	100 (95.9, 100)
CDQ Other depression syndrome* *	90.9 (88.5, 92.9)	93.5 (90.0, 96.0)	83.6 (75.8, 89.7)	85.4 (76.3, 92.0)	89.3 (82.7, 94.0)	100 (95.9, 100)

*If an answer to Q1 or Q2 ≥2 and five or more answers to any Q3-Q9 ≥2;

** If answer to Q1 or Q2 ≥2 and 2+ of answers to any Q3-Q9 ≥2.

Table 4. Positive predictive value and Negative Predictive value of the PHQ-9, PHQ-2 and the CDQ major and other depression syndrome against a psychiatric diagnosis (current depression).

	Overall	Cameroon	Congo	Kenya	Cote d'Ivoire	Senegal
	Positive Predictive Values					
PHQ-9 ≥5	18.0 (13.4, 23.3)	7.8 (2.6, 17.3)	12.9 (5.7, 23.9)	18.2 (8.2, 32.7)	27.9 (17.2, 40.9)	36.8 (16.3, 61.6)
PHQ-9 ≥8	26.1 (18.9, 34.4)	11.1 (2.4, 29.2)	18.4 (7.7, 34.3)	21.4 (8.3, 41.0)	42.9 (26.3, 60.7)	66.7 (22.3, 95.7)
PHQ-9 ≥10	38.0 (26.8, 50.3)	17.7 (3.8, 43.3)	29.4 (10.3, 56.0)	37.5 (15.2, 64.6)	60.0 (36.1, 80.9)	100 (2.5, 100)
PHQ-9 ≥12	43.2 (28.4, 59.0)	16.7 (2.1, 48.4)	41.7 (15.2, 72.3)	55.6 (21.2, 86.3)	60.0 (26.2, 87.8)	100 (2.5, 100)
PHQ-9 ≥15	45.5 (24.4, 67.8)	28.6 (3.7, 71.0)	60.0 (14.7, 94.7)	66.7 (9.4, 99.2)	42.9 (9.9, 81.6)	
PHQ-9 ≥18	66.7 (29.9, 92.5)	50.0 (6.8, 93.2)	50.0 (1.3, 98.7)	100 (2.5, 100)	100 (15.8, 100)	
PHQ-9 ≥20	71.4 (29.0, 96.3)	66.7 (9.4, 99.2)	100 (2.5, 100)	100 (2.5, 100)	100 (15.8, 100)	
PHQ-2 ≥3	17.9 (11.9, 25.2)	8.1 (1.7, 21.9)	9.1 (1.9, 24.3)	17.9 (6.1, 36.9)	30.6 (16.4, 48.1)	50.0 (11.8, 88.2)
CDQ Major	42.9 (21.8, 66.0)	12.5 (0.3, 52.7)	60.0 (14.7, 94.7)	100 (15.8, 100)	40.0 (5.3, 85.3)	100 (2.5, 100)

depression syndrome*						
CDQ Other depression syndrome*	28.3 (19.4, 38.6)	13.6 (2.9, 34.9)	20.0 (6.8, 40.7)	31.6 (12.6, 56.6)	44.0 (24.4, 65.1)	100 (2.5, 100)
Negative Predictive Values						
PHQ-9 ≥ 5	98.3 (96.8, 99.2)	99.6 (97.6, 100)	97.1 (90.1, 99.7)	98.2 (90.1, 99.9)	100 (95.9, 100)	93.9 (86.3, 98.0)
PHQ-9 ≥ 8	97.0 (95.4, 98.2)	98.9 (96.8, 99.8)	96.8 (91.0, 99.3)	95.7 (88.0, 99.1)	98.2 (93.8, 99.8)	91.6 (84.1, 96.3)
PHQ-9 ≥ 10	96.2 (94.5, 97.5)	98.9 (96.9, 99.8)	95.7 (90.2, 98.6)	96.3 (89.7, 99.2)	96.1 (91.1, 98.7)	89.0 (81.2, 94.4)
PHQ-9 ≥ 12	95.2 (93.4, 96.7)	98.6 (96.5, 99.6)	95.8 (90.5, 98.6)	95.5 (88.9, 98.8)	92.0 (86.2, 96.0)	89.0 (81.2, 94.4)
PHQ-9 ≥ 15	94.2 (92.2, 95.7)	98.6 (96.5, 99.6)	94.5 (89.0, 97.8)	92.6 (85.4, 97.0)	90.1 (83.9, 94.5)	88.1 (80.2, 93.7)
PHQ-9 ≥ 18	93.7 (91.8, 95.4)	98.6 (96.5, 99.6)	93.1 (87.3, 96.8)	91.8 (84.4, 96.4)	89.7 (83.6, 94.1)	88.1 (80.2, 93.7)
PHQ-9 ≥ 20	93.6 (91.7, 95.3)	98.6 (96.6, 99.6)	92.4 (86.4, 96.3)	91.8 (84.4, 96.4)	89.7 (83.6, 94.1)	88.1 (80.2, 93.7)
PHQ-2 ≥ 3	95.4 (93.5, 96.9)	98.9 (96.7, 99.8)	92.9 (86.0, 97.1)	94.3 (86.0, 98.4)	94.6 (88.7, 98.0)	90.5 (82.8, 95.6)
CDQ Major depression syndrome*	94.0 (92.1, 95.6)	98.3 (96.0, 99.4)	94.5 (89.0, 97.8)	92.7 (85.6, 97.0)	89.5 (83.3, 94.0)	89.0 (81.2, 94.4)
CDQ Other depression syndrome*	95.9 (94.1, 97.3)	98.9 (96.9, 99.8)	95.3 (89.4, 98.5)	96.2 (89.3, 99.2)	95.1 (89.7, 98.2)	89.0 (81.2, 94.4)

*If an answer to Q1 or Q2 ≥ 2 and five or more answers to any Q3-Q9 ≥ 2 ;

** If answer to Q1 or Q2 ≥ 2 and 2+ of answers to any Q3-Q9 ≥ 2 .

Table 5. Positive and Negative likelihood ratios for PHQ-9 and PHQ-2 against a psychiatric diagnosis (current depression).

	Cameroon		Congo		Kenya		Cote d'Ivoire		Senegal		Overall	
	LR+	LR-	LR+	LR-	LR+	LR-	LR+	LR-	LR+	LR-	LR+	LR-
PH Q-9 ≥ 5	4.11 (2.37, 5.85)	0.21 (0.00, 0.58)	1.81 (1.14, 2.47)	0.36 (0.00, 0.81)	2.20 (1.45, 2.95)	0.19 (0.00, 0.53)	2.97	0	4.33 (1.25, 7.40)	0.48 (0.16, 0.81)	2.93 (2.45, 3.42)	0.23 (0.09, 0.37)
PH Q-9 ≥ 8	6.06 (0.68, 11.44)	0.54 (0.11, 0.98)	2.75 (1.36, 4.15)	0.40 (0.02, 0.79)	2.70 (1.11, 4.28)	0.44 (0.03, 0.86)	5.78 (3.24, 8.32)	0.14 (0.00, 0.32)	14.83 (0.00, 38.37)	0.68 (0.41, 0.91)	4.73 (3.46, 6.00)	0.41 (0.26, 0.56)
PH Q-9 ≥ 10	10.40 (0.53, 20.26)	0.53 (0.10, 0.95)	5.08 (0.91, 9.25)	0.55 (0.21, 0.90)	5.93 (1.52, 10.35)	0.38 (0.03, 0.72)	11.56 (3.03, 20.09)	0.31 (0.08, 0.54)			8.20 (4.99, 11.42)	0.53 (0.39, 0.67)
PH Q-9 ≥ 12	9.70 (0.00, 22.17)	0.69 (0.30, 1.08)	8.71 (0.44, 16.98)	0.53 (0.20, 0.86)	12.36 (0.00, 26.23)	0.47 (0.12, 0.81)	11.56 (0.00, 24.97)	0.67 (0.43, 0.90)			10.16 (4.79, 15.53)	0.67 (0.54, 0.80)
PH Q-9 ≥ 15	19.40 (0.00, 47.08)	0.68 (0.29, 1.06)	18.30 (0.00, 48.84)	0.71 (0.42, 1.00)	19.78 (0.00, 65.28)	0.79 (0.51, 1.06)	5.78 (0.00, 13.92)	0.85 (0.66, 1.04)			11.14 (2.31, 19.97)	0.83 (0.72, 0.93)
PH Q-9 ≥ 18	48.5 (0.00, 135.10)	0.67 (0.29, 1.05)	12.20 (0.00, 45.09)	0.91 (0.71, 1.10)	∞	0.91 (0.72, 1.10)		0.86 (0.64, 1.09)			26.74 (0.00, 63.06)	0.89 (0.81, 0.98)
PH Q-9 ≥ 20	97.0 (0.00, 316.24)	0.67 (0.29, 1.05)	0	1.01 (0.99, 1.02)	∞	-		0.86 (0.64, 1.09)			33.43 (0.00, 87.45)	0.91 (0.83, 0.99)
PH Q-2 ≥ 3	4.28 (0.60, 7.96)	0.57 (0.11, 1.02)	1.22 (0.00, 2.44)	0.93 (0.54, 1.32)	2.15 (0.68, 3.62)	0.60 (0.16, 1.04)	3.39 (1.70, 5.08)	0.44 (0.15, 0.72)	7.42 (0.00, 18.41)	0.78 (0.52, 1.03)	2.91 (1.94, 3.87)	0.64 (0.48, 0.80)

MDD: major depression disorder as diagnosis by a psychiatrist. LR+ = positive likelihood ration, LR- = negative likelihood ratio